The Economic Times

JM Financial calls Metropolis Healthcare best-value diagnostic stock, sees up to 27% upside

JM Financial has retained its Buy rating on Metropolis Healthcare with a target price of Rs 734, implying 27.2% upside. The brokerage calls it the cheapest among Indias leading listed diagnostic players, citing attractive valuations, network expansion, stronger B2C growth and improving margins as key drivers.